Impact of OMEGA-3 fatty acid in patients undergoing hemodialysis: a systematic review and meta-analysis Authors: Hafiz Bilal Ahmed Jilani, Burhan Mazhar Baig, Anas Rasool, Muhammad Ibrahim, Ayan Khalid, Muhammad Shaharyar Rizvi, Shaikh Muhammad Daniyal, Amna Amir Jalal, Alishba Arfan, Zaid Abdul Samad, Muhammad Saad, Hammad Rao, Junaid Jalaluddin, Romal Jabarkhil Published: 2026 ABSTRACT AbstractBackgroundCardiovascular disease is the leading cause of death among patients undergoing hemodialysis, while effective preventive strategies remain limited. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated cardiovascular benefits in the general population. We evaluated the effects of n-3 PUFA supplementation in adults receiving hemodialysis.MethodsPubMed, Embase, and CENTRAL were searched through November 2025 for randomized controlled trials (RCTs) comparing n-3 PUFAs versus placebo in adult hemodialysis patients. Data were pooled using a random-effects model and reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). Subgroup analyses were performed based on Diabetes, Hypertension, Age and Follow-up.Resultsn-3 PUFA supplementation did not significantly reduce all-cause mortality (RR = 0.93; 95% CI 0.80–1.08; p = 0.33). In contrast, cardiovascular mortality was significantly reduced (RR = 0.55; 95% CI 0.42–0.71; p < 0.001) along with fewer vascular access related events (RR = 0.83; 95% CI 0.73–0.95; p = 0.005). significant effects were observed for fatal or non-fatal MI (RR = 0.50; 95% CI 0.36–0.68; p < 0.001).Conclusionsn-3 PUFA supplementation significantly reduces cardiovascular mortality, myocardial infarction, and vascular access events in hemodialysis patients without affecting all-cause mortality. While these findings support n-3 PUFAs as adjunctive cardioprotective therapy in this population, the concentration of evidence in a single large trial warrants cautious interpretation, and confirmation from further large RCTs remains necessary.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05140-4.Keywords: Hemodialysis, Omega-3 PUFA, Cardiovascular mortality, Randomized controlled trials Introduction Chronic kidney disease (CKD) is a major global health burden, affecting approximately 788 million people and ranking as the ninth leading cause of death worldwide [1]. A significant proportion of patients progress to end-stage kidney disease (ESKD), requiring hemodialysis as the most common form of renal replacement therapy [2]. Long-term hemodialysis is associated with a high complication burden, particularly cardiovascular disease (CVD), which is the leading cause of death in this population [3]. Cardiovascular mortality in hemodialysis patients is 10- to 20-fold higher than in the general population [4]. Risk escalates markedly during the transition to dialysis [5]. Omega-3 polyunsaturated fatty acid supplementation has been proposed as a potential intervention to mitigate cardiovascular risk in these patients. It may improve lipid profiles and reduce inflammation, both relevant to CVD pathophysiology in CKD [6–8]. These mechanistic properties provide a biological rationale for potential cardiovascular benefit; however, it is important to note that mechanistically plausible interventions have not always translated into clinical benefit in the ESKD population, underscoring the need for direct trial evidence rather than reliance on biological plausibility alone. Prior meta-analyses evaluating n-3 PUFA supplementation in hemodialysis patients have demonstrated cardiovascular benefits in this population. However, evidence specific to the hemodialysis population is limited by small or outdated studies [9, 10]. Recent randomized controlled trials, such as the PISCES trial, has provided updated evidence, reporting favorable effects of omega-3 on specific cardiovascular risk markers [11]. This persistent evidence gap means clinical guidelines lack clear recommendations. Therefore, this systematic review and meta-analysis aims to provide an updated synthesis of randomized evidence on the effects of omega-3 supplementation on cardiovascular outcomes, kidney function, and mortality in patients with CKD undergoing hemodialysis, to inform future practice and guidelines. Methods This systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12, 13]. The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; Registration ID: CRD420251268564. Objectives and eligibility criteria Studies were considered eligible if they: (i) were randomized controlled trials (RCTs); (ii) compared fish oil or omega-3-polyunsaturated fatty acid (PUFA) supplementation with placebo; (iii) enrolled adult patients receiving maintenance hemodialysis; and (iv) reported at least one outcome of interest. Studies were excluded if they (i) were observational, nonrandomized, or quasi-experimental in design; (ii) enrolled patients receiving peritoneal dialysis or kidney transplant recipients; (iii) included mixed dialysis populations without separately reported data for hemodialysis patients; (iv) did not report relevant outcomes; (v) had overlapping study populations; or (vi) were non-original publications, including editorials, letters, case reports, or case series. Conference abstracts were eligible for inclusion provided they were published in indexed supplement issues of peer-reviewed journals and reported sufficient quantitative data to permit meta-analytic pooling. Literature search strategy Two investigators (BA and AR) independently conducted a comprehensive search across PubMed, Embase, and the Cochrane Central Register of Controlled Trials from inception up to November 2025. The search strategy incorporated all relevant PubMed entry terms. Search terms were used in multiple combinations to maximize sensitivity. The complete search strategies for each database are detailed in Supplementary Table S1. In addition, reference lists of included articles, prior meta-analyses, and related reviews were screened to identify any additional eligible studies. All records were imported into Rayyan.ai for deduplication and screening [14]. Titles and abstracts were reviewed first, followed by full-text assessment to confirm eligibility. Discrepancies were resolved through discussion with a third reviewer (BMB). Data extraction and risk of bias assessment Data were extracted independently by two reviewers (MI and BA). The following variables were extracted from each included study: study characteristics (first author, study design, and follow-up duration); intervention details (drug dosage); and participant characteristics including sample size, age, sex. Baseline clinical variables extracted included the presence of diabetes and hypertension. Discrepancies between reviewers were resolved through discussion or by consulting a third reviewer (AR). Risk of bias was assessed using the Cochrane Risk of Bias 2.0 (RoB 2.0) tool for randomized controlled trials [15]. The predefined outcomes of interest comprised primary outcomes of all-cause mortality and cardiovascular mortality, and secondary outcomes including vascular access related events, and fatal or non-fatal myocardial infarction. All-cause mortality was defined as death from any cause during the follow-up period. Cardiovascular mortality was defined as death attributable to any cardiac or vascular cause, including fatal myocardial infarction, sudden cardiac death, fatal stroke, heart failure, or cardiac arrest. Vascular access events were defined as any complication arising from arteriovenous fistulas or grafts, including thrombosis, stenosis, loss of patency, infection, bleeding, and any radiological or surgical intervention performed to facilitate or maintain patency. Statistical analysis All statistical analyses were conducted using the R. For dichotomous outcomes, risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Pooled effect estimates were derived using a random-effects model with between-study variance (τ²) estimated via Restricted Maximum Likelihood (REML) [16]. Forest plots were created to visually represent the analysis. Publication bias was assessed visually using funnel plots and statistically using Egger’s test, with a p-value of less than 0.05 considered indicative of significant asymmetry (Supplementary Figs 4–9). Heterogeneity across included studies was assessed using Cochran’s Q test and quantified using Higgins I². GRADE evaluation has also been performed. Prespecified subgroup analyses were performed by age (≥ 60 vs. <60 years); diabetes proportion (≥ 50% vs. < 50%); hypertension proportion (≥ 50% vs. <50%); and follow-up duration (> 6 months vs. ≤ 6 months). The Chi-square test was performed to assess differences between the subgroups. These thresholds were exploratory and represented pragmatic median splits rather than clinically prespecified cutoffs. A pre-specified sensitivity analysis was also conducted by excluding studies rated as high risk of bias, as recommended by Cochrane and PRISMA guidelines, to assess the robustness of the primary findings (Supplementary Fig. 10–12). Sensitivity analyses included leave-one-out cross-validation to evaluate the robustness of the results (Supplementary Fig. 13–15). Results A comprehensive search across various electronic databases initially identified 1608 records. After the removal of 263 duplicate records, 1345 unique articles remained. A preliminary screening of titles and abstracts was conducted based on predefined exclusion criteria, leading to the elimination of 1296 articles. A rigorous full-text evaluation was then conducted on 49 reports by two independent reviewers, applying both inclusion and exclusion criteria. This process reduced the number of relevant studies to 13 [11, 17–28], all of which met the inclusion criteria. The PRISMA flowchart in Fig. 1 outlines the systematic screening process. PRISMA flowchart Baseline characteristics and bias analysis Thirteen RCTs (n = 2,755) of patients undergoing hemodialysis were included in this meta-analysis, comparing omega-3 polyunsaturated fatty acids (n-3 PUFAs; n = 1,375) with placebo (n = 1,380). The mean age was 60.93 years in the n-3 PUFA group and 61.67 years in the placebo group. The overall proportion of males was 62.44% in the n-3 PUFA cohort and 61.51% in the placebo cohort. Detailed study characteristics are presented in Table 1. Table 1Key baseline characteristicsStudyNo. of patientsMale, n (%)Age (mean ± SD)*RangeHypertension (%)Diabetes (%)Follow up (months)Dose (g/day)IntConTotalIntConIntConIntConIntConCharmaine E. Lok 20256106181228377 (62.2)387 (63.1)64.1 (13.5)64.5 (13.8)522 (85.6)516 (83.5)342 (56.1)330 (53.4)422.4Irish 2017284283567180 (63)179 (63)54.1 (14)55.6 (14.5)247 (87)255 (91)139 (49)125 (45)124Asemi 201630306020 (66.7)20 (66.7)55.2 (17)59.9 (15.7)9 (30.0)10 (33.3)10 (33.3)10 (33.3)31.25Bowden 20071415296 (40)7 (50)61 (13)63 (11)NRNR9 (31.03)11 (37.93)84Diskin 1990437NRNRNRNRNRNRNRNR63Gharekhani 201425204513 (52)12 (60)56.8 (13.09)57.2 (15.19)9 (36)8 (40)12 (48)7 (35)41.8Hung 201417173414 (82)13 (77)48.55 (16.16)54.44 (16.16)NRNR06 (1)32.9Jabbari 2016576011742 (73.7)33 (55)64.58 (12.61)61.05 (17.42)15 (26.3)30 (50.0)33 (57.9)33 (55.0)33Daud 201231326320 (62.5)12 (38.7)59 (13)58 (13)NRNR20 (62.5)20 (64.5)62.4Lok 2012999719647 (47)51 (53)62.5 (28–88)*63.4 (27–87)*84 (85)84 (87)51 (52)52 (54)124Nasu 2013899017963 (70.9)63 (70)62.0 (11.5)62.7 (10.9)78 (87.6)73 (81.1)26 (29.2)26 (28.9)241.8Svensson 200610310320669 (67)64 (62)66 (11)68 (12)2124NRNR22.4Schmitz 20021212245 (42)6 (50)52 (6)54 (3)NRNR7 (58)7 (58)124 Key baseline characteristics Risk of bias assessment (RoB 2) across 13 RCTs showed variable quality: 4 studies at low overall risk (Irish 2017, Lok 2012, Lok 2025, Svensson 2006), 5 with some concerns (Asemi 2015, Daud 2012, Hung 2015, Nasu 2013, Schmitz 2002), and 4 at high risk (Bowden 2007, Diskin 1990, Gharekjani 2014, Jabbari 2016) (Supplementary Fig. 1a and b). Outcomes All-cause mortality All-cause mortality was reported in 10 studies comprising 2,570 participants. Meta-analysis demonstrated that omega-3 supplementation did not significantly reduce all-cause mortality compared with control [RR 0.93, 95% CI 0.80 to 1.08; p = 0.327; Q = 7.51, df = 9, p = 0.584; I² = 0%; Fig. 2]. Subgroup analysis did not demonstrate effect modification by diabetic prevalence (p-interaction = 0.73), hypertension prevalence (p-interaction = 0.26), age (p-interaction = 0.95), or follow-up duration (p-interaction = 0.27) (Supplementary Fig. 2A-D). In the sensitivity analysis excluding studies at high risk of bias, the pooled risk ratio remained consistent with the primary analysis (Supplementary Fig. 10) Forest plot showing the effect of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation versus placebo on all-cause mortality in patients undergoing hemodialysis Cardiovascular mortality Cardiovascular mortality data were available from eight studies including 2,273 patients. Pooled analysis showed that omega-3 supplementation significantly reduced cardiovascular mortality compared with control [RR 0.55, 95% CI 0.42 to 0.71; p < 0.001; Q = 3.66, df = 7, p = 0.818; I² = 0%; Fig. 3]. Subgroup analysis did not demonstrate effect modification by diabetic prevalence (p-interaction = 0.44), hypertension prevalence (p-interaction = 0.93), age (p-interaction = 0.87), or follow-up duration (p-interaction = 0.70) (Supplementary Fig. 3A-D). In the sensitivity analysis excluding studies at high risk of bias, the pooled risk ratio remained consistent with the primary analysis (Supplementary Fig. 11). Forest plot showing the effect of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation versus placebo on cardiovascular mortality in patients undergoing hemodialysis Vascular access related events Data from six studies encompassing 2,020 patients were used to assess the incidence of vascular access events, with the results showing a significant reduction with Omega-3 supplementation [RR: 0.83 (95% CI: 0.73 to 0.95; p = 0.005; Q = 6.86, df = 5, p = 0.232; I² = 27.1% Fig. 4]. In the sensitivity analysis excluding studies at high risk of bias, the pooled risk ratio remained consistent with the primary analysis (Supplementary Fig. 12). Forest plot showing the effect of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation versus placebo on vascular access events in patients undergoing hemodialysis Fatal or non-fatal MI A pooled analysis of two studies encompassing 1,434 patients revealed that Omega-3 supplementation significantly reduced the risk of Fatal and Non-Fatal MI [RR: 0.50 (95% CI: 0.36 to 0.68; p < 0.001; Q = 0.80, df = 1, p = 0.37; I² = 0.0%; Fig. 5]. Forest plot showing the effect of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation versus placebo on the occurrence of fatal or non-fatal MI in patients undergoing hemodialysis Discussion Pooling data from 2,755 patients, this meta-analysis brings together the latest evidence on omega-3 fatty acid (n-3 PUFA) supplementation in individuals receiving hemodialysis, revealing meaningful clinical benefits. The findings point to statistically significant reductions in cardiovascular mortality, fatal and non-fatal MI, alongside fewer vascular access–related events. To our knowledge, this represents the most comprehensive meta-analysis to date on n-3 PUFA supplementation in hemodialysis patients, exclusively synthesizing evidence from RCTs to ensure a rigorous evaluation of both safety and efficacy. All-cause mortality The pooled analysis demonstrated no significant reduction in all-cause mortality with n-3 PUFA supplementation. Additionally, this neutral finding was consistent across all pre-specified subgroup analyses; one plausible explanation behind this is the overwhelming burden of competing, non-cardiovascular mortality risks in this frail population, such as infections and protein-energy wasting, which are not modified by n-3 PUFA therapy [29, 30]. This observation aligns with prior meta-analyses in general cardiovascular populations, which often report neutral effects on all-cause mortality [31, 32]. Cardiovascular mortality In stark contrast, n-3 PUFA supplementation was associated with a significant 45% relative risk reduction in cardiovascular mortality. Subgroup analyses confirmed this benefit was consistent irrespective of diabetic or hypertensive prevalence and patient age. Notably, the benefit was most pronounced in follow-up periods exceeding six months, suggesting the cardioprotective mechanisms require sustained exposure. This robust effect is likely attributable to the specific high-risk profile of the hemodialysis population, which includes severe chronic inflammation and often critically low baseline n-3 PUFA levels [33, 34]. This group may therefore derive disproportionately greater benefit from supplementation than the general population. The finding is supported by the recent PISCES trial, which reported a 44% relative reduction in serious cardiovascular events in hemodialysis patients receiving daily fish oil [11]. Several caveats warrant consideration. First, cardiovascular death definitions were not formally standardized across all included studies. However, the three largest contributing trials, accounting for the overwhelming majority of statistical weight, employed substantively identical definitions encompassing sudden cardiac death, fatal MI, fatal stroke, and death from heart failure, each adjudicated by independent events committees [11, 23, 25]. Variation was therefore limited to ascertainment rigor rather than fundamental outcome definition, a position corroborated by the absence of statistical heterogeneity across the pooled estimate. Second, two of the eight contributing studies, specifically Diskin 1990 [20] and Gharekhani 2014 [21], were rated at high overall risk of bias and enrolled fewer than 30 patients each. A sensitivity analysis excluding these trials confirmed directional consistency of the result. Third, the dissociation between cardiovascular and all-cause mortality is mechanistically explicable: a large portion of the deaths are attributable to infection, sepsis, malnutrition, and dialysis withdrawal are not modified by n-3 PUFA therapy [29, 30]. Readers are nonetheless advised to interpret the magnitude of this effect with caution pending confirmation from larger prospectively adjudicated trials. Vascular access events Another key finding from this updated meta-analysis was the significant reduction in vascular access events, which are a major cause of morbidity in this population [35, 36]. This outcome included thrombosis, stenosis, loss of patency infection, bleeding, and any radiological or surgical intervention to facilitate or maintain patency in arteriovenous fistulas and grafts [11, 18, 20, 23, 25, 26] is a major cause of morbidity in hemodialysis [37, 38]. In contrast to our finding, prior evidence concluded that the effect of n-3 PUFAs on vascular access patency was uncertain [9]. The significant risk reduction as demonstrated by our analysis might be attributable to the inclusion of recent high-quality RCTs [11]. The proposed mechanisms underlying this finding involve the anti-thrombotic, anti-inflammatory, and endothelial-stabilizing properties of n-3 PUFAs, which modulate key pathways implicated in neointimal hyperplasia and thrombosis [38–39]. Myocardial infarction (fatal and non-fatal) The pooled analysis demonstrated a significant reduction in fatal and non-fatal myocardial infarction with n-3 PUFA supplementation. This finding is biologically plausible and convergent with evidence from broader cardiovascular populations, where n-3 PUFA supplementation has been associated with modest but consistent reductions in MI, particularly at higher doses [40]. The hemodialysis population may derive particular benefit given the heightened susceptibility to arrhythmia-driven cardiac events conferred by dialysis-related haemodynamic instability and electrolyte flux, a context in which the anti-arrhythmic properties of n-3 PUFAs [41] may be especially consequential. The anti-thrombotic and endothelial-stabilising effects of n-3 PUFAs [37–39] provide additional mechanistic support for a reduction in plaque rupture-mediated MI in this population. This finding is further consistent with the broader pattern of cardiovascular benefit observed across the other outcomes in this meta-analysis, suggesting a coherent and pleiotropic cardioprotective effect of n-3 PUFA supplementation in hemodialysis patients. Nevertheless, given that this estimate is derived from only two trials, definitive conclusions cannot be drawn, and larger prospectively adjudicated studies are warranted to confirm this finding. Other considerations and safety Although not a primary outcome of this meta-analysis, the safety profile of n-3 PUFAs warrants consideration. Notably, broader meta-analyses consistently identify an increased risk of atrial fibrillation (AF) as a potential harm associated with pharmaceutical dosing [42]. This risk must be balanced against the demonstrated benefits of reduced cardiovascular mortality and vascular access events when considering the use of n-3 PUFA in clinical practice. Strengths, limitations, and clinical implications The strength of this review lies in its rigorous methodology, including only RCTs to ensure high methodological rigour, subgroup analyses, and the incorporation of pivotal recent trial data, such as the Lok 2025 trial, which substantially updated the evidence base for this population. It should be noted, however, that Lok 2025 enrolled approximately 43% of the total study population across all included trials, and pooled estimates must therefore be interpreted with this concentration of evidence in mind. Furthermore, the included studies span an extreme range of sample sizes (n = 7 to 1,228), daily doses (1.25 g to 4 g), and follow-up durations (2 to 42 months), reflecting substantial clinical heterogeneity that limits the generalisability of the pooled estimates. The dominance of this single trial on the pooled estimates is acknowledged as a key limitation, and readers are cautioned to interpret results accordingly. Some additional limitations must be acknowledged. Variability in dose and formulation (EPA/DHA ratio) and the lack of granular data on the duration of n-3 PUFA regimens across the included trials precluded subgroup analysis by duration. The composite nature of the vascular access outcome, which encompasses thrombosis, stenosis, infection, bleeding, and radiological or surgical interventions, limits the mechanistic interpretability of this analysis, as these constituent events are pathophysiologically distinct and may respond differently to omega-3 supplementation. This reflects the reporting practices of the primary studies rather than a methodological choice of the review authors, as no included trial disaggregated vascular access events into their constituent components. As a study-level meta-analysis, our findings are also subject to aggregation bias and limited adjustment for patient-level confounders, which could be addressed in future individual participant data meta-analyses. From a clinical standpoint, these findings suggest that n-3 PUFA supplementation in hemodialysis patients should not be viewed as a broad mortality-reducing strategy. Instead, it emerges as a targeted adjunctive therapy with promising applications in secondary cardiovascular prevention, particularly for reducing cardiovascular death and myocardial infarction, and in the preservation of vascular access integrity. Conclusion In summary, n-3 PUFA supplementation provides significant and clinically meaningful reductions in cardiovascular mortality, myocardial infarction, and vascular access events in patients undergoing hemodialysis. These benefits occur without a measurable impact on all-cause mortality, reflecting the multifaceted risk profile in end-stage renal disease where competing non-cardiovascular risks dilute the overall survival benefit. The evidence supports the consideration of n-3 PUFAs as an adjunctive therapy for specific cardioprotective and vascular access-related goals in this high-risk population. Nevertheless, the concentration of evidence in a single large trial, and the limited number of trials contributing to certain outcomes necessitate cautious interpretation, and confirmation from further large, prospectively adjudicated RCTs remains warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements None. Abbreviations Chronic Kidney Disease End–Stage Kidney Disease Hemodialysis Cardiovascular Disease Omega–3 Polyunsaturated Fatty Acids Randomized Controlled Trial Risk Ratio Mean Difference Confidence Interval Author contributions Anas Rasool, Ayan Khalid and Burhan Mazhar Baig contributed to the conceptualization and methodology of the study. Shaikh Muhammad Daniyal and Hafiz Bilal Ahmed Jilani were responsible for software, validation, and formal analysis. The investigation, data curation, and resources were managed by Muhammad Ibrahim, Zaid Abdul Samad, and Muhammad Saad. The original draft was written by Muhammad Shaharyar Rizvi, Alishba Arfan and Amna Amir jalal. Reviewing and editing of the manuscript were performed by Hammad Rao, Junaid Jalaluddin, and Romal Jabarkhil. Funding The authors received no financial support for the research, authorship, and/or publication of this article. Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval The study used publicly available and de-identified data. Hence, ethical approval was not required for this study. Consent for publication Patient consent is not required for the publication of this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.